AstraZeneca to establish strategic R&D centres
- Details
- Category: AstraZeneca
AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.
Merck announces collaboration with nordic Bioscience for Sprifermin
- Details
- Category: Merck Group
Merck today announced a strategic alliance with Nordic Bioscience Clinical Development A/S on Merck's investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis (OA) of the knee. This agreement underscores Merck's commitment to osteoarthritis research and development.
Shire acquires Premacure AB
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially blinding eye disorder that primarily affects premature infants and is one of the most common causes of visual loss in childhood.
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
- Details
- Category: Boehringer Ingelheim
In parallel with the American College of Cardiology (ACC) Scientific Sessions in San Francisco, initial results have been released from a physician educational programme being undertaken to rectify misunderstandings on stroke prevention in atrial fibrillation (AF) in China. The programme offered by the ACC and the Chinese Society of Cardiology with the support of Boehringer Ingelheim, is part of wider international educational activities.
Bayer to collaborate with the Children's Hospital & Research Center Oakland to fight rare blood diseases
- Details
- Category: Bayer
Bayer HealthCare has signed a master collaboration agreement with the California-based Children's Hospital & Research Center Oakland to research hemoglobin disorders, particularly in the area of sickle cell anemia. The agreement aims to utilize promising research approaches to help identify potential new therapies for the rare blood disease.
United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex®
- Details
- Category: Pfizer
Pfizer Inc. announced that the United States Patent & Trademark Office has granted Pfizer a reissue patent (U.S. Patent No. RE44048), covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex®.
Australia Federal Court holds CRESTOR patents invalid
- Details
- Category: AstraZeneca
AstraZeneca today announced that the Federal Court of Australia has found three patents protecting CRESTOR (rosuvastatin) to be invalid. These patents - a formulation patent (AU 200051842, with an expiry date in 2020); a second related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (AU 2002214165, with an expiry date in 2021); and a third related to the use of rosuvastatin for treating hypercholesterolemia (AU 2000023051, with an expiry date in 2020) - were challenged by Apotex Pty Ltd, Watson Pharma Pty Ltd and Ascent Pharma Pty Ltd.
More Pharma News ...
- Bayer: continuing growth momentum
- Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
- Roche launches new process for accessing clinical trial data
- Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of patients with gastrointestinal stromal tumors
- FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
- Abbott to collaborate with Janssen and Pharmacyclics
- New findings from two studies support substantial benefit of Pradaxa®